INTHER SIGNED
Clinical validation and commercialization of innovative immunostimulating Interstitial Laser Thermotherapy
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0INTHER project word cloud
Explore the words cloud of the INTHER project. It provides you a very rough idea of what is the project "INTHER" about.
Project "INTHER" data sheet
The following table provides information about the project.
| Coordinator |
CLINICAL LASERTHERMIA SYSTEMS AB
Organization address contact info |
| Coordinator Country | Sweden [SE] |
| Project website | http://www.clinicallaser.se |
| Total cost | 2˙136˙357 € |
| EC max contribution | 2˙136˙357 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2016-2017 |
| Funding Scheme | SME-2 |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-08-01 to 2018-11-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CLINICAL LASERTHERMIA SYSTEMS AB | SE (LUND) | coordinator | 2˙136˙357.00 |
Map
Project objective
The INTHER project will bring the groundbreaking immunostimulating Interstitial Laser Thermotherapy (imILTCLS) to the market and clinical practice. This minimally invasive therapy is designed to achieve local tumour destruction and stimulate specific antitumour immunity in a patient’s body. In recent years, anti-cancer therapies based on activation of the immune system have grown in significance and popularity. This approach is especially viable for patients who previously had very few treatment options. However, only approx. 20 % of all patients respond to drug-based immunotherapies of today. The key need of medical oncologists is to increase those response rates and thus decrease cancer-related suffering, increase life expectancy and survival rates for the patients. The project will meet those needs by delivering a novel device-based cancer immunotherapy method that destroys the tumour locally and induces long-lasting, vaccination-like, systemic immunity against the treated form of cancer. As the world’s first device-based laser immunotherapy, imILTCLS will curve its own market niche on the fast growing Cancer Immunotherapy Market and therefore have a significant disruptive effect on this market. The studies performed to date have confirmed the therapeutic capability of the new method. In the project, the method will be further validated for the two chosen solid tumour types: pancreatic cancer and breast cancer. This will enable CLS to shorten the time to full commercialisation, obtain the clinical acceptance and fully exploit the commercial potential of the new treatment method. The clinical uptake of imILTCLS in Europe will lead to reduction of costs associated with the treatment of solid tumours, especially surgeries, and reduction of costs related to the activation of immunotherapies. CLS’ strategy is based on intensive efforts towards validating imILTCLS and bringing it to the market. The project is a key step towards realizing this business strategy.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2017 |
Axelsson J, Pantaleone C, Åström S Initial Findings of Immunostimulating Interstitial Laser Thermotherapy of Solid Tumours published pages: 28-31, ISSN: 1758-5678, DOI: |
Journal for Clinical Studies volume 9, issue 4 | 2019-06-12 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "INTHER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "INTHER" are provided by the European Opendata Portal: CORDIS opendata.